Live
FierceBiotechAI could help spot heart disease in routine breast mammogram screeningsBioPharma DiveVertex kidney disease drug hits mark in late-stage studyThermo FisherThermo Fisher looks to shake up Bay Area biotech with 10-foot microscope - The Business JournalsIlluminaSPT-Illumina partnership ‘delivers core facilities to decentralised labs’ - Cambridge IndependentBioPharma DiveBristol Myers claims success in study of another next-gen blood cancer drugLonza NewsBRIEF—Lonza and Genetix Biotherapeutics extend deal - The Pharma LetterEndpoints NewsIpsen pulls cancer drug Tazverik from market over safety risksEndpoints NewsWhat Prasad's exit means for the FDA moving forwardAgilentAgilent Technologies to acquire Biocare Medical in $950m deal - Yahoo FinanceBioPharma DiveRoche’s prized breast cancer pill fails closely watched studyFierceBiotechTenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater ChinaFierceBiotechFDA greenlights backup anti-choking suction device
Endpoints News Jan 21, 2026

IntraBio says rare disease drug passes Phase 3, will seek FDA approval

IntraBio says rare disease drug passes Phase 3, will seek FDA approval

Original
Body unavailable. Use the original source.

Directory

59 All